In 2022, the upward trajectory continued as Pfizer saw revenues exceed $100 billion for the first time in company history. Impressively, $61 billion of the company’s sales was derived from products launched in just the last three years, the most of any pharma company ever assessed in the subset of the PIII known as the ‘Freshness Index’.​

​As was the case in 2021, the key driver of Pfizer’s growth came from the company’s COVID-19 products, Comirnaty (tozinameran) and Paxlovid (nirmatrelvir/ritonavir). While Comirnaty continued to be the company's top performer, generating nearly $38 billion in sales, it was the addition of the COVID-fighting antiviral, Paxlovid (granted emergency use authorization in December 2021) that propelled the company to its new height, generating $18.9 billion in sales this past year. For context, AbbVie’s arthritis and psoriasis treatment Humira, the world’s best-selling drug for over a decade, managed $21.2 billion in 2022 sales.​

​Pfizer once again showed off its adaptability and agility, leveraging its mRNA platform to swiftly create an updated vaccine for the Omicron BA.4 and BA.5 subvariants. In under a year from the variant’s detection, the company had a new bivalent vaccine booster authorized by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), a true testament to the company’s innovation in action.

In addition to its record-breaking COVID-19 portfolio, Pfizer attained eight additional regulatory nods in 2022, including two for novel medicines. The two novel medicines being Vydura (rimegepant), the first medicine approved for both acute and prophylactic treatment of migraine in the European Union (EMA), and Cibinqo (abrocitinib) to treat adults with moderate-tosevere, refractory atopic dermatitis (FDA).

Pfizer was also busy putting its hard-earned cash to work with four acquisitions: Arena Pharmaceuticals, Biohaven Pharmaceuticals, Global Blood Therapeutics, and ReViral, which should further strengthen its pipeline and portfolio of products for years to come.